Literature DB >> 19450632

ISCOMs and ISCOMATRIX.

Hong-Xiang Sun1, Yong Xie, Yi-Ping Ye.   

Abstract

Immunostimulatory complexes (ISCOMs) are particulate antigen delivery systems composed of antigen, cholesterol, phospholipid and saponin, while ISCOMATRIX is a particulate adjuvant comprising cholesterol, phospholipid and saponin but without antigen. The combination of an antigen with ISCOMATRIX is called an ISCOMATRIX vaccine. ISCOMs and ISCOMATRIX combine the advantages of a particulate carrier system with the presence of an in-built adjuvant (Quil A) and consequently have been found to be more immunogenic, while removing its haemolytic activity of the saponin, producing less toxicity. ISCOMs and ISCOMATRIX vaccines have now been shown to induce strong antigen-specific cellular or humoral immune responses to a broad range of antigens of viral, bacterial, parasite origin or tumor in a number of animal species including non-human primates and humans. These vaccines produced by well controlled and reproducible processes have also been evaluated in human clinical trials. In this review, we summarize the recent progress of ISCOMs and ISCOMATRIX, including preparation technology as well as their application in humans and veterinary vaccine designs with particular emphasis on the current understanding of the properties and features of ISCOMs and ISCOMATRIX vaccines to induce immune responses. The mechanisms of adjuvanticity are also discussed in the light of recent findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450632     DOI: 10.1016/j.vaccine.2009.05.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

1.  Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

Authors:  Kae Pusic; Hengyi Xu; Andrew Stridiron; Zoraida Aguilar; Andrew Wang; George Hui
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

2.  Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.

Authors:  Emmanuel Tupin
Journal:  Hum Vaccin Immunother       Date:  2013-07-29       Impact factor: 3.452

3.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

Review 4.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

5.  Nanomedicine in the Management of Microbial Infection - Overview and Perspectives.

Authors:  Xi Zhu; Aleksandar F Radovic-Moreno; Jun Wu; Robert Langer; Jinjun Shi
Journal:  Nano Today       Date:  2014-08-01       Impact factor: 20.722

6.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Authors:  Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder
Journal:  Blood Adv       Date:  2017-11-17

7.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

Review 8.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

9.  Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route.

Authors:  Aurélie Girard; Elodie Roques; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

10.  Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.

Authors:  Robyn Marty-Roix; Gregory I Vladimer; Kimberly Pouliot; Dan Weng; Rachel Buglione-Corbett; Kim West; John D MacMicking; Jonathan D Chee; Shixia Wang; Shan Lu; Egil Lien
Journal:  J Biol Chem       Date:  2015-11-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.